Jim Cramer Shed Light on These 8 Stocks Recently

1. AbbVie Inc. (NYSE:ABBV)

Number of Hedge Fund Holders: 68

During the episode, Cramer noted AbbVie Inc.’s (NYSE:ABBV) success and called it a buy.

“Oh, AbbVie is just a gem and… They bought a company that with something, it failed and no one even cared when it had to do with brain work. AbbVie is a winner. I can’t believe the stock dropped so much. I think AbbVie is a buy.”

AbbVie Inc. (NYSE:ABBV) is a pharmaceutical company involved in the research, development, production, and promotion of a wide variety of medicines. Polaris Capital Management stated the following regarding AbbVie Inc. (NYSE:ABBV) in its Q3 2024 investor letter:

“U.S. biopharma/biotech companies topped the health care sector, with the majority of holdings posting returns in excess of 10%. AbbVie Inc. (NYSE:ABBV) showed positive top-line growth from its immunosuppressive drugs, Skyrizi and Rinvoq. Abbvie’s management continues to work through the loss of exclusivity from Humira, switching patients to Skyrizi or Rinvoq rather than Humira biosimilars.”

While we acknowledge the potential of AbbVie Inc. (NYSE:ABBV) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than ABBV but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap.

Disclosure: None. This article was originally published at Insider Monkey.